Subject Index

N-acetyl-leucinyl-leucinyl-norleucinal (ALLN), proinflammatory cytokine reduction 221

Aging
anorexia of the elderly, see Anorexia
muscle loss, see Sarcopenia
nutritional status changes over lifetime
body composition 31, 32
determinants 32
heritability 36–40
metabolic impact 33–36
methodological issues in characterization 32, 33, 41–43
weight loss versus weight gain 31

Albumin
malnutrition assessment 85, 86
predictive value in cancer patients 131

Alcohol
acute effects in brain 194
chronic effects on immune system in stress 194, 195

Alcoholism, weight loss 170

Anorexia
elderly
pathological causes 170, 171
physiological causes 17, 167, 168
sociological causes 16, 17
nutritional interventions 19
pharmacological interventions 20

starvation versus cachexia 18, 19

Anthropometry
malnutrition assessment 77, 78, 85
oral protein and energy supplementation trial meta-analysis, elderly 114, 117

Anti-chymotrypsin, inflammation marker 9

Appetite
exercise effects 173, 174
food quantity versus quality 177

Arginine, supplementation precautions in burn patients 232

Aspiration, high-risk patients 100, 101

Bioelectrical impedance analysis (BIA)
body composition change measurement over lifetime 32, 33, 41
precision of measurements 42
principles 78

B lymphocytes
adaptive immune response to commensal intestinal bacteria 209, 210

immune response 190

Body cell mass (BCM)
clinical consequences of loss 76, 77
cutoff points for health-related risks 73, 74, 80, 81
Subject Index

Body mass index (BMI)
cutoff points for health-related risks 81
heritability 39, 40
targeting in fracture prevention 240, 241

Cachexia
cytokine roles 27, 170
definition 167, 169
distinguishing from starvation 18, 19
pathogenesis 170, 171

Calcium
birth weight effects on levels 237
fracture risk reduction 237, 238
supplementation in the elderly 175

Cancer
total parenteral nutrition comparison trials
advantages and disadvantages 135, 136
complications 130, 131, 132
home enteral nutrition 132–135
mortality 130
nutritional status 130–132
patient preferences 136
tumor growth rate effects 141, 142
weight loss in the elderly 171

Cannabinoids, undernutrition intervention in the elderly 20

Celiac disease, HLA DR2 phenotype
187

Child growth
food insecurity relationship 2–4
impairment consequences 5, 6
inflammation relationship 4, 5

Cholecystokinin, aging effects on levels 168

Cimetidine, weight loss 170

Cloricromene, proinflammatory cytokine reduction 221

Computed tomography (CT), body composition measurements 43

Coping, stress effects on immune response studies 202

Corticotropin-releasing factor, exercise induction 174

Cortisol
immune suppression by stress 193, 198, 199, 201
proinflammatory cytokine inhibition strategies 223

C-reactive protein (CRP)
depression association 201, 202

environmental factors in reduction
12, 13
heart disease risks 28
inflammation marker 9, 87
periodontitis 28
stress effects on levels 200

Curcumin, proinflammatory cytokine reduction 220

Dehydration, mortality 165, 166

Delayed skin hypersensitivity response, malnutrition assessment 86

Dementia
home enteral nutrition 144
weight loss 170, 176, 177

Dendritic cell (DC), modulation of intestinal flora effects on immune system 204, 205, 207, 209, 210

Depression
stress association 201, 202
weight loss 170

Desferrioxamine, proinflammatory cytokine reduction 225

Digoxin, weight loss 170

Dual-energy X-ray absorptiometry (DEXA)
body composition measurements 41–43
principles 78, 79

Economics
cost analysis parameters 156, 157
ethical considerations 156–159
home enteral nutrition
Europe 64, 66–71
United States 45, 46, 52, 54, 71

Elderly
energy intake 15
nutritional status 15, 16
oral protein and energy
supplementation trial meta-analysis
anthropometry 114, 117
benefits 117, 118
complications 105, 114
description of studies 105–112
design of trials 121, 122
hospital stay length 105, 114, 115
micronutrient supplementation as confounding factor 124
mortality outcomes and subgroup analysis 105, 113, 122
selection of studies 104, 105
weight change 114, 116

252
undernutrition
  frequency in acute hospitals 20
  medical illness causes 17, 18, 170, 171
  nutritional interventions 19, 25, 26
  pharmacological interventions 20
  physiological causes 17, 167, 168
  sociological causes 16, 17
  vitamin supplementation 174, 175
Energy intake, nursing home diets 174, 175
Enteral nutrition (EN), see also Home enteral nutrition
cancer patient studies of enteral nutrition versus total parenteral nutrition comparison trials
  advantages and disadvantages 135, 136
  complications 130, 131, 132
  home enteral nutrition 132–135
  mortality 130
  nutritional status 130–132
  patient preferences 136
  tumor growth rate effects 141, 142
  goals in terminal illness 152, 153
  metabolic effects compared with total parenteral nutrition 128, 129
  termination ethics 153, 154
Etanercept, undernutrition intervention in the elderly 20
Ethics
economic considerations 156–159
  home enteral nutrition in the United States 68, 69
  informed consent 163, 164
  legal considerations 154, 155, 161, 162
  morality 148
  nutritional support termination 153, 154, 161
  pediatric nutritional support 155, 156
  percutaneous endoscopic gastrostomy in terminal illness 68, 69, 99, 146, 147
  religion 148–150
  self-determination and medical decision making 150–152, 161, 162
  'vegetative' patient nutritional support withdrawal 153
Exercise
  appetite effects 173, 174
  corticotropin-releasing factor
    induction 174
  elderly patients 25, 26
  energy intake versus exercise insufficiency in obesity 173
Fat-free mass (FFM)
  heritability 37, 38
  measurement 32, 33, 73, 77–79
  metabolic impact of age-related changes 33, 34
  nutritional status changes over lifetime 31
  physiological mechanisms of loss 74, 75
Fat mass (FM)
  heritability 37, 38
  measurement 32, 33, 77–79
  metabolic impact of age-related changes 33, 34
  nutritional status changes over lifetime 31
Fluoxetine, weight loss 170
Folate, supplementation 175
Food insecurity
  child growth relationship 2–4
  poverty relationship 1
Fractures
  birth weight effects on bone health 237
  calcium and vitamin D in risk reduction 237, 238
  health care service interventions for prevention
    community interventions 238–240
    hospital interventions 240
  targeting of interventions 240, 241
Glutamine, proinflammatory cytokine reduction 224, 225, 229
Gut-associated lymphoid tissue (GALT), intestinal microbiota interactions 205
Health outcomes
dimensions 233–235
  health care service interventions
    community interventions 238–240
    hospital interventions 240
  targeting of interventions 240, 241
  health professionals
    attitudes 234, 235
    training 242, 243
  interventions across lifecourse
    adults 237, 238
    children and adolescents 237
    disability threshold reduction 238
Subject Index

Health outcomes (continued)
  interventions across lifecourse
    (continued)
  fetus 236, 237
  overview 235, 236
  societal differences in prioritization 234

Home enteral nutrition (HEN)
  cancer patients 132–135
  definition 59, 60
  delivery options 51, 52, 62, 63
  dementia patients 144
  enteral access options and devices
    49, 50
  Europe
    frequency of use 60, 61, 66, 67
    funding 64, 66–71
    indications 62, 67
    legislation 63, 64, 69, 70
    patient characteristics 61
  formulas 51, 62, 63
  historical perspective 45
  monitoring 51–53
  nutritional status outcomes 91–93
  pediatric outcomes 49, 67
  quality of life 47, 48, 56, 93, 94
  recommended dietary allowances in
    disease 99
  risk/benefit ratio analysis 89, 90
  safety 46, 55, 90, 91
  support in United Kingdom
    inequity 241, 242
    quality 242
  survival 48, 49, 55–57, 90, 91, 94–97
  United States
    demographics 46
    economics and reimbursement 45,
      46, 52, 54, 71
    ethics 68, 69
    indications 46
    nursing home use 54, 56

Human immunodeficiency virus (HIV),
  malnutrition impact in developing
  countries 1

Ibuprofen, proinflammatory cytokine
  inhibition 223
Inalopret, proinflammatory cytokine
  reduction 230

Inflammation, chronic
  child growth relationship 4, 5, 9
  degenerative diseases 5, 6

environmental factors in reduction
  12, 13
proinflammation pathways 6, 7, 75
proinflammatory cytokines, see also
  specific cytokines
  manipulation
    anti-inflammatory cytokines 223,
      224
    production inhibitors 220–222,
      230
    prospects 225, 226
  target cell interaction and
    signaling interference 222, 223
  nutrient studies
    amino acids 231, 232
    glutamine 224, 225
    omega-3 fatty acids 225
  stress role 199, 200
Informed consent, nutritional support
  163, 164
Insulin-like growth factor-1 (IGF-1),
  aging decline and sarcopenia 169, 219
Interleukin-1 (IL-1), inhibition strategies
  223
Interleukin-6 (IL-6)
  catabolism role 75
  sarcopenia role 169
Interleukin-10 (IL-10), proinflammatory
cytokine counteraction 223, 224

Intestine
  barrier
    bacteria and substrate effects on
      function 181–183
    structure 179, 180
  microbiota
    adaptive immune response to
      commensals 209, 210
    commensals versus pathogenic
      bacteria 187, 188
    dendritic cell interactions 204, 205,
      207, 209, 210
    differential innate response to
      bacteria 207–209
    enteral nutrition effects 183
    fecal short-chain fatty acid studies
      214, 215
    health and disease 180, 181
    host interaction biology 205–207
    hygiene hypothesis 210
    immune function interactions 204,
      205
<table>
<thead>
<tr>
<th>Subject</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant diet effects</td>
<td>215, 216</td>
</tr>
<tr>
<td>Intestinal epithelial cell</td>
<td>sensing of bacterial signals</td>
</tr>
<tr>
<td>Modulation with prebiotics</td>
<td>and probiotics</td>
</tr>
<tr>
<td>Neonatal colonization</td>
<td>215</td>
</tr>
<tr>
<td>Probiotic supplementation</td>
<td>effects</td>
</tr>
<tr>
<td>Permeability</td>
<td></td>
</tr>
<tr>
<td>Antibiotic effects</td>
<td>187</td>
</tr>
<tr>
<td>Assays</td>
<td>180, 185</td>
</tr>
<tr>
<td>Diabetics</td>
<td>188</td>
</tr>
<tr>
<td>Inflammation and malnutrition</td>
<td>11, 185, 186</td>
</tr>
<tr>
<td>Irritable bowel syndrome</td>
<td>(IBS)</td>
</tr>
<tr>
<td>Intestinal microbiota</td>
<td>214</td>
</tr>
<tr>
<td>Stress role</td>
<td>186</td>
</tr>
<tr>
<td>Isohelenin, proinflammatory cytokine reduction</td>
<td>222</td>
</tr>
<tr>
<td>Leptin</td>
<td></td>
</tr>
<tr>
<td>Sympathetic nervous system</td>
<td>link</td>
</tr>
<tr>
<td>Testosterone relationship</td>
<td>168</td>
</tr>
<tr>
<td>Living will</td>
<td></td>
</tr>
<tr>
<td>Durable power of attorney</td>
<td>164, 165</td>
</tr>
<tr>
<td>Self-determination and</td>
<td>Medical decision making</td>
</tr>
<tr>
<td>Lymphocyte count, malnutrition assessment</td>
<td>86</td>
</tr>
<tr>
<td>Macrophages, immune response</td>
<td>189, 190</td>
</tr>
<tr>
<td>Magnetic resonance imaging (MRI), body composition measurements</td>
<td>43</td>
</tr>
<tr>
<td>Malnutrition assessment</td>
<td>77–79, 244–247</td>
</tr>
<tr>
<td>Causes</td>
<td>73</td>
</tr>
<tr>
<td>Clinical consequences</td>
<td>76, 77</td>
</tr>
<tr>
<td>Definition</td>
<td>73, 101</td>
</tr>
<tr>
<td>Health risks</td>
<td>80</td>
</tr>
<tr>
<td>Immune response suppression</td>
<td>mechanisms</td>
</tr>
<tr>
<td>Megestrol acetate,</td>
<td>undernutrition intervention</td>
</tr>
<tr>
<td>Melatonin, undernutrition</td>
<td>intervention in the elderly</td>
</tr>
<tr>
<td>Membrane potential decrease in stress</td>
<td>88</td>
</tr>
<tr>
<td>Nasogastric tube,</td>
<td>reimbursement rate</td>
</tr>
<tr>
<td>Natural killer cells,</td>
<td>immune response</td>
</tr>
<tr>
<td>Nitrogen balance</td>
<td>protein turnover assessment</td>
</tr>
<tr>
<td>Nuclear factor-κB (NF-κB)</td>
<td>Antioxidant inhibition of</td>
</tr>
<tr>
<td>Curcumin inhibition</td>
<td>activation</td>
</tr>
<tr>
<td>Isohelenin inhibition</td>
<td>222</td>
</tr>
<tr>
<td>Toll-like receptor signal transduction</td>
<td>206, 208, 209</td>
</tr>
<tr>
<td>Nutritional support</td>
<td>initiation, ethical concerns</td>
</tr>
<tr>
<td>Obesity, energy intake</td>
<td>versus exercise insufficiency</td>
</tr>
<tr>
<td>Omega-3 fatty acids</td>
<td>proinflammatory cytokine</td>
</tr>
<tr>
<td>Wound healing studies in rats</td>
<td>231</td>
</tr>
<tr>
<td>Pediatric nutritional</td>
<td>support ethics</td>
</tr>
<tr>
<td>Home enteral nutrition</td>
<td>outcomes</td>
</tr>
<tr>
<td>Pentoxifylline, proinflammatory cytokine reduction</td>
<td>27, 220</td>
</tr>
<tr>
<td>Percutaneous endoscopic</td>
<td>gastrostomy (PEG)</td>
</tr>
<tr>
<td>Aspiration high-risk patients</td>
<td>100, 101</td>
</tr>
<tr>
<td>Ethics in terminal illness</td>
<td>68, 69, 99, 146, 147</td>
</tr>
<tr>
<td>Indications</td>
<td>146, 147</td>
</tr>
<tr>
<td>Reimbursement rate for</td>
<td>feedings</td>
</tr>
<tr>
<td>Survival</td>
<td>57, 90, 91, 94–97</td>
</tr>
<tr>
<td>Prealbumin, malnutrition</td>
<td>assessment</td>
</tr>
<tr>
<td>Probiotics</td>
<td>Immunocompromised patient risks</td>
</tr>
<tr>
<td>Intestinal microbiota</td>
<td>modulation</td>
</tr>
<tr>
<td>Live organism versus DNA</td>
<td>effects</td>
</tr>
<tr>
<td>Supplementation effects in</td>
<td>enteral nutrition</td>
</tr>
</tbody>
</table>

255
Psychoneuroimmunobiology
definition 189
historical perspective 199
immune response overview 189–192
mechanisms of stress modulation 193–196
psychological stress effects on immune response 192, 193

Religion, considerations in nutritional support initiation 148–150
Resting energy expenditure (REE)
heritability 37, 38
impact of age-related changes in body composition 33–36

Sarcopenia
cytokine induction 24, 219
definition 167
pathogenesis 24, 169
Selenium, proinflammatory cytokine reduction 225
Self-determination, considerations in nutritional support initiation 150–152, 161, 162
Skeletal muscle mass index (SMI), cutoff points for health-related risks 81, 82
Starvation
definition 167
distinguishing from cachexia 18, 19
Statins, cytokine reduction 28, 230
Stress, see also
Psychoneuroimmunobiology
classification 201, 202
gastric effects 200, 201
inflammation 199, 200
irritable bowel syndrome role 186
membrane potential effects 88

Testosterone
leptin relationship 168
undernutrition intervention in the elderly 23, 24
Thalidomide, tumor necrosis factor-α reduction 27
Theophylline, weight loss 170
T lymphocytes
immune response 190, 191
intestinal flora effects on immune system 204, 205
proliferation 192
stress response 192–194
T helper subsets 191, 192, 213, 219
Toll-like receptors (TLRs)
differential innate immune response to intestinal bacteria 207–209
intestinal epithelial cell sensing of bacterial signals 205, 206
signal transduction 206, 208, 209
soluble receptors 207
Total parenteral nutrition (TPN)
cancer patient studies of enteral nutrition versus total parenteral nutrition comparison trials advantages and disadvantages 135, 136
complications 130, 131, 132
home enteral nutrition 132–135
mortality 130
nutritional status 130–132
patient preferences 136
tumor growth rate effects 141, 142
goals in terminal illness 152, 153
historical perspective 143
home parenteral nutrition 139, 140, 144, 163, 164
metabolic effects compared with enteral nutrition 128, 129
survival rates in cancer 143, 144
termination ethics 153, 154
Tumor necrosis factor-α (TNF-α)
antibody neutralization 222
cytokine interactions 228
ketotifen inhibition 230
polymorphisms and overexpression 228, 229
thalidomide reduction 27

‘Vegetative’ patients, nutritional support withdrawal ethics 153
Vitamin C, proinflammatory cytokine reduction 225
Vitamin D
birth weight effects on levels 237
fracture risk reduction 237, 238
supplementation in the elderly 175
Vitamin E, proinflammatory cytokine reduction 225
Zinc
deficiency and hypogeusia 168
proinflammatory cytokine reduction 225